ArticleScientific reports2018
miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Ion channel and biophysical properties of extracellular vesicles.The Journal of biological chemistry · 2026Review
- Identification and validation of hub genes involved in papillary thyroid carcinoma progression.BMC cancer · 2026Article
- Expression and significance analyses of microRNAs in colorectal cancer.Molecular and clinical oncology · 2026Article
- The microRNAs landscape of luminal B breast cancer cells in a three-dimensional microenvironment.Hereditas · 2025Article
- Article
- Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma.Molecular therapy. Oncology · 2024Review
- Comprehensive characterization of RNA cargo of extracellular vesicles in breast cancer patients undergoing neoadjuvant chemotherapy.Frontiers in oncology · 2022Article
- Emerging Evidence of the Functional Impact of the miR379/miR656 Cluster (C14MC) in Breast Cancer.Biomedicines · 2021Review
- The effect of miR-539 regulating TRIAP1 on the apoptosis, proliferation, migration and invasion of osteosarcoma cells.Cancer cell international · 2021Article
- Identification of Potential lncRNAs and miRNAs as Diagnostic Biomarkers for Papillary Thyroid Carcinoma Based on Machine Learning.International journal of endocrinology · 2021Article
- Cell-free DNA promotes malignant transformation in non-tumor cells.Scientific reports · 2020Article
- Construction and investigation of a combined hypoxia and stemness index lncRNA-associated ceRNA regulatory network in lung adenocarcinoma.BMC medical genomics · 2020Article
- The anti-tumor effect of miR-539-3p on colon cancer via regulating cell viability, motility, and nude mouse tumorigenicity with CDK14 inhibition.Journal of gastrointestinal oncology · 2020Article
- A SNP-mediated lncRNA (LOC146880) and microRNA (miR-539-5p) interaction and its potential impact on the NSCLC risk.Journal of experimental & clinical cancer research : CR · 2020Article
- Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer.Non-coding RNA · 2020Review
- VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.Oncogene · 2020Article
- Long Noncoding RNA LINC00460 Modulates MMP-9 to Promote Cell Proliferation, Invasion and Apoptosis by Targeting miR-539 in Papillary Thyroid Cancer.Cancer management and research · 2020Article
- Differentiating Grade in Breast Invasive Ductal Carcinoma Using Texture Analysis of MRI.Computational and mathematical methods in medicine · 2020Article
- Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients.Oncotarget · 2019Article
- MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer.British journal of cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer-associated death in women worldwide. microRNAs (miRNAs) play critical roles in the cellular processes of breast cancer. However, the crucial roles and underlying mechanisms of miR-539 in breast cancer remain unclear. By RT-qPCR, we found that expression of miR-539 was markedly down-regulated in breast cancer tissues and cell lines compared with that in paired adjacent normal tissues and normal cell lines. The low level of miR-539 expression was positively associated with lymph node metastasis. Furthermore, forced expression of miR-539 inhibited proliferation and migration of breast cancer MDA-MB-231 and MCF7 cells in vitro and suppressed tumor growth in vivo. Moreover, bioinformatics analysis and luciferase reporter assays indicated that epidermal growth factor receptor (EGFR) was a direct target of miR-539. Over-expression of miR-539 decreased the EGFR mRNA and protein levels in MDA-MB-231 and MCF7 cells. In addition, ectopic over-expression of EGFR partly reversed miR-539-inhibited proliferation as well as migration of MDA-MB-231 and MCF7 cells. Taken together, our results demonstrate that miR-539 functions as a tumor suppressor in breast cancer by downregulating EGFR, supporting the targeting of the novel miR-539/EGFR axis as a potentially effective therapeutic approach for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.